Acadia Pharmaceuticals Inc. is providing this letter in response to your unsolicited request for medical information. It is for scientific-exchange and individual educational purposes only, and should not be copied or distributed. Information included in this letter may not be consistent with the US FDA-approved Prescribing Information for NUPLAZID® (pimavanserin) or may be related to unapproved uses of NUPLAZID. This letter is not intended to advocate any unapproved or approved use, indication, dosage, or other treatment-related decision. Acadia strives to provide current, accurate, and fair-balanced information in compliance with current industry information dissemination guidelines.

For further information regarding Indication, **Boxed WARNING** and other Important Safety Information for NUPLAZID, please click here: Prescribing Information.

12830 El Camino Real · Suite 400 · San Diego, California 92130 · USA · Tel. 858.558.2871 · Fax 858.558.2872 · acadia.com

NUPLAZID® (pimavanserin) Discontinuation

> This letter is being provided based on your specific request for information on how to discontinue treatment with pimavanserin.

There was no protocol for participants discontinuing pimavanserin in the Acadia-sponsored clinical trial program in Parkinson's disease psychosis.[1-4] Acadia Pharmaceuticals Inc. does not have any additional information regarding how to discontinue pimavanserin.

The mean plasma half-lives for pimavanserin and the active metabolite (N-desmethylated metabolite) are approximately 57 hours and 200 hours, respectively.[5] Physicians should exercise clinical judgment when discontinuing this product.

References

1. Acadia Pharmaceuticals Inc. Data on File. ACP-103-006 Protocol. 2003.
2. Acadia Pharmaceuticals Inc. Data on File. ACP-103-012 Protocol. 2007.
3. Acadia Pharmaceuticals Inc. Data on File. ACP-103-014 Protocol. 2008.
4. Acadia Pharmaceuticals Inc. Data on File. ACP-103-020 Protocol. 2010.
5. NUPLAZID® (pimavanserin) [package insert]. San Diego, CA. Acadia Pharmaceuticals Inc. **[Link]**